Table 1.
Expression of HER3 in different types of cancer detected by immunohistochemistry (IHC) in the selected studies.
| Cancer Type | % of HER3 Overexpression | Antibody Used in IHC | Cutoff for Overexpression | Reference |
|---|---|---|---|---|
| Pancreatic | 41.3% | Nanotools, Teningen, Germany | Moderate staining is observed in >10% of tumor cells (score 2+), and strong staining is observed in >10% of tumor cells (score 3) | [56] |
| Breast | 43.0% | Clone 2F12, Labvision, Cheshire, UK | Positive: Optimal cutoffs for HER2:HER3 dimers were assessed by performing a minimum P value estimation using approximate 5% cutoffs across the entire dataset using relapse-free survival as an endpoint | [57] |
| 17.5% | IgG1, Neomarkers, UK | 4-point scale, where 0 = no staining, 1 = light staining, 2 = moderate staining, and 3 = strong staining | [58] | |
| Colorectal | 17.0% | MAb-MS-725-P, Neomarkers, Fremont, CA | Membranous staining: >1% of tumor cells stained. Cytoplasmic staining: 2+: moderate immunostaining in >10% of tumor cells and 3+: strong immunostaining in >10% of tumor cells | [59] |
| 69.7% | Lab Vision, Fremont, CA Cytoplasmic and membrane Cytoplasmic | Cytoplasmic staining: 0: no staining or weak staining in <10% of tumor cells. membranous staining: 0: no staining in <10% of tumor cells; 1: weak staining in >10% tumor cells; 2+: moderate staining in > 10% tumor cells; 3: strong staining in >10% tumor cells |
[59] | |
| 20.9% | Clone C-17, 1:50; Santa Cruz, CA | Depending on the intensity of staining, HER3 expression was classified as weak, intermediate, or strong | [60] | |
| Gastric | 59.0% | Mouse monoclonal antibody, Neomarkers | 2+ = moderate staining, and 3+ = strong staining | [61] |
| 34.0% | RB-9211 rabbit polyclonal, dilution 1:100, N terminal; Neomarkers, Fremont, CA | 0 = <10% of positively stained cells; 1 = 10–25%; 2 = 26–50%; 3 = 51–75%; 4 = >75% | [52] | |
| Melanoma | approximately 65.0% | Clone C-17, 1:50 dilution; SantaCruz, CA | Positive: high GIS > 6 (GIS: German immunohistochemical scoring) | [60] |
| Ovary | 53.4% | C-17, rabbit polyclonal antibody; dilution: 1:25; Santa Cruz, CA | Positive: scores >8 | [62] |
| Head and Neck | 8.8% | RTJ.2, mouse monoclonal antibody; Santa Cruz, CA | Scores of 0, +1, +2, and +3 for increasing intensity | [55] |
| Cervix | 55.5% | MS-725-P, mouse antibody; Neomarkers | Intensity scale 0–4 based on pixel density | [63] |